Pharmaceutical Finished Formulation Registration in Bolivia: Complete Regulatory Framework, Dossier Checklist, and Compliance Strategy

🇧🇴 Regulatory Framework & Governing Authorities in Bolivia

Bolivia maintains a strict and centralized pharmaceutical regulatory system designed to protect public health and ensure that only safe, effective, and high-quality medicines reach the market. All finished pharmaceutical formulations, whether locally manufactured or imported, are legally required to obtain Sanitary Registration (Registro Sanitario) prior to commercialization.

The regulatory framework is well-defined, enforceable, and supervised by a single national authority, making compliance non-negotiable for pharmaceutical manufacturers, exporters, and marketing authorization holders seeking access to the Bolivian market.

Product Name	Brand Name (TAJ Format)	Pack Size	Therapeutic Category	Dosage Form	Available Strengths	BCS Class (Estimate)
Acitretin	ACITRETAJ	10×10	Dermatology (Retinoid)	Capsule	10 mg, 25 mg	II
Atomoxetine	ATOMOXTAJ	10×10	CNS (ADHD)	Capsule	10, 18, 25, 40, 60, 100 mg	I
Atorvastatin Calcium	ATORVATAJ	10×10 / 10×3	Dyslipidemia	Tablet	20, 40, 80 mg	II
Atorvastatin + Ezetimibe	ATOR-EZETTAJ	10×10	Dyslipidemia	Tablet	10+10, 10+20, 10+40 mg	II
Azithromycin	AZITHROTAJ	10×3	Antibiotic (Macrolide)	Tablet	250, 500, 600 mg	II
Bisoprolol Fumarate	BISOPROTAJ	10×10	Cardiovascular	Tablet	1.25, 2.5, 5, 10 mg	I
Bisoprolol Fumarate + Hydrochlorothiazide	BISOP-HTZTAJ	10×10	Antihypertensive	Tablet	2.5+6.25, 5+6.25, 5+12.5, 10+6.25 mg	I
Brivaracetam	BRIVATAJ	10×10	Antiepileptic	Tablet	25, 50, 75, 100 mg	I
Carbamazepine CR	CARBATAJ-CR	10×10	Antiepileptic	Tablet	100, 200, 300, 400 mg	II
Carbamazepine CT	CARBATAJ-CT	10×10	Antiepileptic	Tablet	100 mg	II
Carbidopa + Levodopa + Entacapone	CARBI-LEVO-ENTATAJ	10×10	Parkinson’s Disease	Tablet	Multiple strengths	I
Carvedilol	CARVETAJ	10×10	Cardiovascular	Tablet	6.25, 12.5, 25 mg	II
Cetirizine	CETIRTAJ	10×10	Anti-allergic	Tablet	5, 10 mg	III
Ciprofloxacin HCl	CIPROTAJ	10×10	Antibiotic (Fluoroquinolone)	Tablet	500 mg	IV
Clarithromycin	CLARITAJ	10×10	Antibiotic (Macrolide)	Tablet	250 mg	II
Desloratadine	DESLORTAJ	10×10	Anti-allergic	Tablet	5 mg	I
Diacerein	DIACETAJ	10×10	Anti-osteoarthritis	Capsule	50 mg	II
Digoxin	DIGOXTAJ	10×10	Cardiac Glycoside	Tablet	0.25 mg	IV
Doxylamine	DOXYLTAJ	10×10	Antihistamine	Tablet	25, 50 mg	I
Duloxetine DR	DULOXTAJ-DR	10×10	CNS (SNRI)	Capsule	20, 30, 40, 60 mg	I
Eslicarbazepine Acetate	ESLITAJ	10×10	Antiepileptic	Tablet	200, 400, 600 mg	II
Fluoxetine	FLUOXTAJ	10×10	Antidepressant (SSRI)	Tablet	10, 20, 40, 60 mg	I
Flurazepam	FLURATAJ	10×10	Sedative-Hypnotic	Capsule	15, 30 mg	I
Furosemide	FUROTAJ	10×10	Diuretic	Tablet	20, 40, 80 mg	IV
Gabapentin	GABATAJ	10×10 / 10×3	Neuropathic Pain	Tablet/Capsule	100, 300, 600, 800 mg	III
Glibenclamide	GLIBETAJ	10×10	Antidiabetic	Tablet	5 mg	II
Glibenclamide + Metformin SR	GLIB-METTAJ	10×10	Antidiabetic	Tablet	1.25+250, 2.5+500, 5+500 mg	III
Hydroxyzine HCl	HYDROXYTAJ	10×10	Anxiolytic / Antihistamine	Tablet	10, 25, 50 mg	I
Levocetirizine	LEVOCETAJ	10×10	Anti-allergic	Tablet	5, 10 mg	III
Levodopa + Benserazide	LEVO-BENZTAJ	10×10	Parkinson’s Disease	Tablet	100+25, 200+50 mg	I
Levofloxacin	LEVOTAJ	10×10	Antibiotic (Fluoroquinolone)	Tablet	250, 500, 750 mg	I
Levonorgestrel	LEVONORTAJ	1×1 / 1×2	Emergency Contraceptive	Tablet	0.75, 1.5 mg	II
Lisinopril + Hydrochlorothiazide	LIS-HTZTAJ	10×10	Antihypertensive	Tablet	10+12.5, 20+12.5, 20+25 mg	III
Loperamide HCl	LOPERTA J	10×10	Antidiarrheal	Tablet	2 mg	II
Loratadine	LORATAJ	10×10	Anti-allergic	Tablet	5, 10 mg	I
Lorazepam	LORAZTAJ	10×10	Anxiolytic	Tablet	2 mg	I
Meloxicam	MELOXTAJ	10×10	NSAID	Tablet	7.5, 15 mg	II
Memantine HCl	MEMANTA J	10×10	Alzheimer’s Disease	Tablet	10 mg	I
Misoprostol	MISOPROTAJ	1×4	Obstetrics/Gynecology	Tablet	100 mcg	I
Modafinil	MODAFINTAJ	10×10	CNS Stimulant	Tablet	100, 200 mg	II
Moxonidine	MOXONTAJ	10×10	Antihypertensive	Tablet	0.2, 0.3, 0.4 mg	I
Naproxen	NAPROTAJ	10×10	NSAID	Tablet	250, 375, 500, 550 mg	II
Olanzapine + Fluoxetine	OLAN-FLUOXTAJ	10×10	Psychiatric	Capsule	3+25, 6+25, 6+50, 12+50 mg	II
Perampanel	PERAMPTAJ	10×10	Antiepileptic	Tablet	2, 4, 6, 8, 10, 12 mg	II
Prednisolone	PREDNITAJ	10×10	Corticosteroid	Tablet	5, 10, 20, 40 mg	I
Pregabalin	PREGATAJ	10×10 / 10×3	Neuropathic Pain	Capsule	25, 50, 75, 100, 150, 200, 300 mg	I
Propranolol HCl	PROPRATAJ	10×10	Beta-Blocker	Tablet	10, 20, 40, 60, 80 mg	I
Rosuvastatin Calcium	ROSUVATAJ	10×10 / 10×3	Dyslipidemia	Tablet	5, 10, 20, 40 mg	II
Rosuvastatin + Clopidogrel	ROSU-CLOPTAJ	10×10	Cardiovascular	Capsule	10+75, 20+75 mg	II
Rosuvastatin + Ezetimibe	ROSU-EZETTAJ	10×10	Dyslipidemia	Tablet	5+10, 10+10, 20+10, 40+10 mg	II
Rosuvastatin + Fenofibrate	ROSU-FENOTAJ	10×10	Dyslipidemia	Tablet	5+67, 10+67, 10+145 mg	II
Saxagliptin + Dapagliflozin	SAXA-DAPATAJ	10×10	Antidiabetic	Tablet	5+10 mg	III
Tapentadol + Carisoprodol	TAPEN-CARISTAJ	10×10	Pain Management	Tablet	225, 450 mg	II
Vonoprazan	VONOPRAJ	10×10	Acid Suppressant	Tablet	10, 20 mg	I

---

Legal Foundations Governing Pharmaceutical Registration

Bolivia’s pharmaceutical regulations are grounded in robust national legislation that establishes mandatory registration, quality control, and post-market surveillance.

Ley del Medicamento – Law No. 1737

This is the cornerstone of Bolivia’s pharmaceutical law. It mandates that manufacture, importation, distribution, marketing, promotion, and use of medicines must be subject to prior sanitary registration. The law defines registration as a rigorous technical and legal evaluation process, ensuring:

• Quality
• Safety
• Therapeutic efficacy

No medicine may legally enter the Bolivian supply chain without approval under this law.

Decreto Supremo No. 25235/1998

This decree serves as the regulatory implementation of Law No. 1737. It defines:

• Registration procedures
• Evaluation timelines
• Authority responsibilities
• Import and commercialization controls
• Administrative sanctions and penalties

It also clarifies that any significant post-approval change (formula, manufacturer, dosage form, strength) requires new registration, not a simple variation.

Reglamento de Farmacias y Laboratorios

This regulation provides operational and technical detail, covering:

• Product classification
• Licensing of manufacturers, importers, and distributors
• Documentation requirements
• Quality validation expectations
• Pharmacist accountability

Together, these instruments form a legally enforceable regulatory ecosystem aligned with WHO principles.

---

Regulatory Authority: AGEMED

The Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) is Bolivia’s national medicines regulatory authority operating under the Ministry of Health and Sports.

AGEMED holds exclusive authority over pharmaceutical regulation, including:

• Evaluation and approval of Sanitary Registration applications
• Control of manufacturing, importation, labeling, and distribution
• Oversight of Good Manufacturing Practices (GMP)
• Post-approval surveillance, renewals, and reinscriptions
• Market inspections and enforcement actions

AGEMED’s decisions are legally binding across the entire Bolivian territory.

---

Scope of Pharmaceutical Products Requiring Registration

Bolivia applies universal registration requirements. The following finished pharmaceutical products must obtain Sanitary Registration before any commercial activity:

• Innovator (brand-name) medicines
• Generic medicines
• Biologicals and vaccines
• Homeopathic and natural medicinal products
• Dental pharmaceutical products
• Cosmetics with therapeutic or medicinal claims

There are no exemptions for imported products or internationally approved medicines.

---

Importer, Manufacturer, and Applicant Eligibility

To apply for registration, the applicant must be a legal entity established in Bolivia, authorized by the Ministry of Health as one of the following:

• Pharmaceutical Manufacturer
• Importer / Distributor
• Local Authorized Representative of a foreign manufacturer

Mandatory requirements include:

• Valid operating license
• Appointment of a licensed Regente Farmacéutico
• Annual reinscription and inspection compliance
• Legal responsibility for pharmacovigilance and product quality

Foreign manufacturers cannot apply directly without a local representative.

---

Pharmaceutical Registration Dossier Structure in Bolivia

Bolivia requires a comprehensive regulatory dossier demonstrating quality, safety, and consistency. While Bolivia has not fully adopted the international CTD format, its Sanitary Registration Manual (RM 0909/2005) closely mirrors CTD Modules 1–3 in practice.

---

Standard Regulatory Dossier Checklist for Bolivia

Module 1 – Administrative & Legal Documentation

• Official Sanitary Registration Application Form
• Signatures of Legal Representative and Regente Farmacéutico
• Applicant operating license and Ministry of Health registration
• Annual inspection and compliance certificates
• Power of Attorney (if applicable)
• Manufacturer authorization and contractual agreements
• WHO-GMP or equivalent GMP Certificate
• Manufacturing license from country of origin
• Product ownership or MAH authorization letter
• Free Sale Certificate (recommended)

---

Module 2 – Product Summary & Regulatory Overview

• Product description and pharmacological classification
• Approved indications and therapeutic use
• Route of administration and dosage form
• Target population
• Prescription or OTC status
• Countries of prior registration (if any)
• Regulatory history and approvals

---

Module 3 – Quality (Core Technical Documentation)

Composition & Formulation

• Full qualitative and quantitative composition
• API identity, grade, and pharmacopeial standard
• Excipient function and justification
• Colorant and preservative compliance
• Overages explained where applicable

API Documentation

• API specifications
• Analytical methods
• Certificates of Analysis
• API manufacturer details
• DMF or CEP (supportive)
• API stability or retest period

Finished Product Manufacturing

• Manufacturing process flowchart
• Batch manufacturing formula
• In-process controls
• Process validation summary
• Packaging operations
• Commercial-scale consistency

Finished Product Specifications

• Release and shelf-life specifications
• Analytical method validation summaries
• Reference standards
• Batch Certificates of Analysis

Stability Studies

• Stability protocol
• Accelerated and long-term data
• Storage conditions
• Shelf-life justification
• Climatic relevance (Zone IVb commonly accepted)

Bolivia applies pragmatic flexibility, but stability data is mandatory.

---

Module 4 – Safety & Efficacy (Simplified)

For generic medicines:

• Bioequivalence study (if available)
• Scientific literature justification
• Reference product identification

For innovator products:

• Clinical summaries or bibliographic data
• International approvals (EMA/FDA supportive)

---

Module 5 – Labeling & Patient Information

• Primary label artwork in Spanish
• Secondary packaging artwork
• Batch number and expiry space
• Storage conditions
• Manufacturer and MAH details
• Space for Sanitary Registration number

Package Insert (Leaflet):

• Indications
• Dosage and administration
• Contraindications
• Warnings and precautions
• Adverse reactions
• Storage instructions

Labeling inconsistencies are one of the most common causes of regulatory queries.

---

Module 6 – Samples & Quality Control

• Commercial-scale product samples
• Retention samples (if requested)
• Consent for testing at CONCAMYT, Bolivia’s National Quality Control Laboratory

---

Module 7 – Declarations & Compliance

• Declaration of document authenticity
• Pharmacovigilance commitment letter
• Commitment to notify regulatory changes
• Compliance declaration with Bolivian laws

---

Registration Evaluation Process

Submission Requirements

• Entire dossier submitted in Spanish
• Physical or AGEMED-approved electronic channels
• Signed and sealed by responsible parties

Evaluation Stages

1. Administrative Screening
2. Technical and Quality Assessment
3. Laboratory Testing (if required)

Any post-approval change involving formulation, manufacturer, or dosage form requires new registration.

---

Timelines, Validity, and Renewals

• Evaluation timeline: 6–12 months
• Sanitary Registration validity: 5 years
• Renewal (Reinscription): Mandatory before expiry
• Updated documentation and batch quality data required

Failure to renew results in automatic invalidation.

---

Post-Approval Surveillance and Compliance

AGEMED enforces active market surveillance, including:

• Product sampling
• Quality testing
• Pharmacovigilance reporting
• Inspection of distributors and pharmacies

Non-compliance may result in seizure, customs rejection, fines, or market withdrawal.

---

Market Compliance and Legal Enforcement

• Importation without Sanitary Registration is strictly prohibited
• Only authorized samples may enter Bolivia
• Counterfeit, adulterated, or non-compliant products are banned
• Regulatory sanctions are actively enforced

---

Strategic Regulatory Insight

Bolivia is a highly regulated but accessible market for pharmaceutical manufacturers that approach registration with technical precision, regulatory discipline, and dossier consistency. A well-prepared registration strategy significantly reduces timelines, queries, and compliance risk.